Greater Biologic Persistence, Adherence Achieved With Ixekizumab for Psoriasis
May 16th 2022, 7:45pm
ArticleSignificantly greater persistence, adherence, and time on monotherapy was achieved with the use of ixekizumab vs the biologics adalimumab, etanercept, secukinumab, and ustekinumab, in the treatment of moderate to severe psoriasis.